Desmoplastic Melanoma: An Updated Immunohistochemical Analysis of 40 cases with a Proposal for an Additional Panel of Stains for Diagnosis.
Milwaukee, United States. In J Cutan Pathol, Jan 2016
The purpose of this study was to analyze 40 cases of DM with a comprehensive panel of immunohistochemical markers (KBA.62, p16, Ezrin, WT-1, MITF-1, SOX-10, CD117, SOX-2, Nestin, PNL2, p75, MART-1, gp100 and S100p) to obtain a more complete understanding of the potential use of these antibodies in the diagnosis of DM.
[Antibody therapies for melanoma].
Chinju, South Korea. In Nihon Rinsho, 2012
Although 10 mg/kg of ipilimumab showed 10-15% of objective response, phase 3 study of ipilimumab with gp100 vaccination or with dacarbazine showed prolonged survival.
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Goshen, United States. In N Engl J Med, 2011
In a previous phase 2 study, patients with metastatic melanoma receiving high-dose interleukin-2 plus the gp100:209-217(210M) peptide vaccine had a higher rate of response than the rate that is expected among patients who are treated with interleukin-2 alone.
Improved survival with ipilimumab in patients with metastatic melanoma.
Boston, United States. In N Engl J Med, 2010
In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma.